3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled